The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
As of close of business last night, Syndax Pharmaceuticals Inc’s stock clocked out at $9.99, down -2.25% from its previous closing price of $10.22. In other words, the price has decreased by -$2.25 from its previous closing price. On the day, 1.33 million shares were traded. SNDX stock price reached its highest trading level at $10.32 during the session, while it also had its lowest trading level at $9.92.
Ratios:
To gain a deeper understanding of SNDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.75 and its Current Ratio is at 5.80. In the meantime, Its Debt-to-Equity ratio is 1.61 whereas as Long-Term Debt/Eq ratio is at 1.54.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Buy rating and assigned the stock a target price of $18.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $37.
On June 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $37.Jefferies initiated its Buy rating on June 28, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 16 ’25 when Goldan Keith A. sold 1,296 shares for $9.29 per share. The transaction valued at 12,033 led to the insider holds 92,450 shares of the business.
Metzger Michael A sold 7,534 shares of SNDX for $69,953 on Jul 16 ’25. The Chief Executive Officer now owns 298,661 shares after completing the transaction at $9.29 per share. On Jul 16 ’25, another insider, Goldan Keith A., who serves as the Officer of the company, bought 1,296 shares for $9.29 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SNDX now has a Market Capitalization of 859613504 and an Enterprise Value of 688931008. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.66 while its Price-to-Book (P/B) ratio in mrq is 4.00. Its current Enterprise Value per Revenue stands at 15.757 whereas that against EBITDA is -2.005.
Stock Price History:
The Beta on a monthly basis for SNDX is 0.74, which has changed by -0.5920784 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, SNDX has reached a high of $25.07, while it has fallen to a 52-week low of $8.58. The 50-Day Moving Average of the stock is 1.07%, while the 200-Day Moving Average is calculated to be -26.72%.
Shares Statistics:
It appears that SNDX traded 2.21M shares on average per day over the past three months and 1627120 shares per day over the past ten days. A total of 86.05M shares are outstanding, with a floating share count of 82.47M. Insiders hold about 4.16% of the company’s shares, while institutions hold 115.50% stake in the company. Shares short for SNDX as of 1751241600 were 23867422 with a Short Ratio of 10.78, compared to 1748563200 on 23140140. Therefore, it implies a Short% of Shares Outstanding of 23867422 and a Short% of Float of 31.330000000000002.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
As of right now, 11.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.93, with high estimates of -$0.72 and low estimates of -$1.09.
Analysts are recommending an EPS of between -$3.17 and -$4.34 for the fiscal current year, implying an average EPS of -$3.77. EPS for the following year is -$2.67, with 11.0 analysts recommending between -$1.63 and -$3.36.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $27.09M. It ranges from a high estimate of $34.1M to a low estimate of $17.44M. As of the current estimate, Syndax Pharmaceuticals Inc’s year-ago sales were $3.5MFor the next quarter, 11 analysts are estimating revenue of $33.24M. There is a high estimate of $43.6M for the next quarter, whereas the lowest estimate is $20.47M.
A total of 11 analysts have provided revenue estimates for SNDX’s current fiscal year. The highest revenue estimate was $154.2M, while the lowest revenue estimate was $83.05M, resulting in an average revenue estimate of $123.82M. In the same quarter a year ago, actual revenue was $23.68MBased on 11 analysts’ estimates, the company’s revenue will be $262.02M in the next fiscal year. The high estimate is $394.74M and the low estimate is $216.9M.
